华法林患者自我管理在非瓣膜性房颤中的成本效果分析
该研究采用Markov模型,从改良社会视角和支付方视角评估70岁及以上非瓣膜性房颤患者终生使用华法林患者自我管理(PSM)对比抗凝管理服务(AMS)和常规护理(UC)的成本效果。结果显示PSM终生成本最低(76,515美元)且QALY最高(8.47),在任何支付意愿阈值下均最具成本效果。
要点
- PSM终生成本76,515美元,低于AMS的129,216美元和UC的137,509美元。
- PSM的QALY为8.47,高于AMS的8.30和UC的8.27。
- PSM显著降低卒中发生率,概率敏感性分析显示其最具成本效果。
核心结论
- PSM是美国70岁及以上NVAF患者华法林管理中最具成本效果的策略,且在任何支付意愿阈值下均如此。
研究设计与样本
- 成本效果分析,采用Markov模型模拟70岁NVAF患者终生,从改良社会视角和支付方视角进行比较。
- 转移概率来自ARISTOTLE试验的年事件率,比较效果与安全性来自网络荟萃分析。
- 成本以2024年美元计,未来成本和结果贴现率3%,并进行单因素和概率敏感性分析。
主要发现
- 改良社会视角终生成本:UC为137,509美元,AMS为129,216美元,PSM为76,515美元。
- 贴现QALY:UC为8.27,AMS为8.30,PSM为8.47。
- PSM较AMS和UC显著降低卒中发生率,从而降低成本并提高QALY。
- 概率敏感性分析显示PSM在任何支付意愿阈值下均最具成本效果。
临床怎么用
- 在美国医疗环境中应考虑实施华法林患者自我管理(PSM)以改善成本效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patient self-management (PSM) is a warfarin management strategy that allows patients to independently adjust their doses. PSM significantly reduces thrombosis events and has been widely implemented internationally. However, adoption of PSM is limited in the United States. This study estimated the cost-effectiveness of PSM compared with available strategies, including anticoagulation management services (AMS) and usual care (UC) for patients with non-valvular atrial fibrillation (NVAF) aged 70 years and older in the United States. METHODS: A cost-effectiveness analysis was performed to estimate lifetime costs and outcomes of PSM compared with AMS and UC employing a Markov model. The model simulated a 70-year-old with NVAF over the patient's lifetime from modified societal and payer perspectives. Transition probabilities were derived from annual event rates reported in the ARISTOTLE trial. Comparative efficacy and safety among the interventions were obtained from a network meta-analysis. Costs, presented in 2024 US dollars (USD), and utility data were obtained from data sources in the United States. A discount rate of 3% was applied for future costs and outcomes. One-way sensitivity analysis and probabilistic sensitivity analysis were performed to assess the robustness of the findings. RESULTS: The lifetime costs from the modified societal perspective were $137,509 USD for UC, $129,216 USD for AMS, and $76,515 USD for PSM. Discounted quality-adjusted life years (QALYs) were estimated to be 8.27 for UC, 8.30 for AMS, and 8.47 for PSM. Additionally, PSM substantially reduced stroke incidence compared with AMS and UC, contributing to lower costs and greater QALYs. Probabilistic sensitivity analysis showed that PSM appeared to be the most cost-effective at any willingness-to-pay threshold. CONCLUSIONS: PSM is the most cost-effective strategy for managing warfarin in the target population at any willingness-to-pay threshold. Implementation of PSM in the US health care setting should be considered.
引用
- Kategeaw W, Witt DM, King JB, et al. Cost-Effectiveness Analysis of Patient Self-Management of Warfarin Among Patients With Non-Valvular Atrial Fibrillation. Pharmacotherapy. 2026. PMID: 42136139. doi:10.1002/phar.70154
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。